Why is telopoietin called the "strongest weight loss drug"? ——The latest clinical trial data reveals

Since its launch, telpotetide has been widely hailed as the " strongest weight-loss drug " due to its remarkable weight-loss effects. Unlike traditional GLP-1 receptor agonists (such as smegglutide), telpotetide is the first GLP-1 + GIP dual agonist , which not only reduces appetite but also promotes fat metabolism and improves insulin sensitivity .

The latest SURMOUNT series of clinical trials have confirmed that telpolide has a significantly better weight loss effect than existing GLP-1 drugs , providing a more efficient weight management solution for obese patients.

 

1. Why is telpolide called the " strongest weight loss drug " ?

Traditional weight-loss drugs (such as semaglutide) primarily rely on GLP-1 action , reducing food intake by suppressing appetite and delaying gastric emptying , but their direct impact on fat metabolism is limited. In contrast, telpolide innovatively combines a dual GLP-1 + GIP agonist mechanism , surpassing existing drugs in several aspects:

•       GLP-1 function (similar to smegglutinin): reduces appetite, slows gastric emptying, and reduces glucagon secretion.

•       GIP function (unique to telpoeptide): promotes fat breakdown, improves insulin sensitivity, and makes it easier for the body to burn stored fat.

Core advantages:

1. Greater weight loss – telpolide is more effective at reducing weight than GLP-1 drugs alone.
2. Higher fat metabolism efficiency – GIP accelerates fat burning rather than simply reducing calorie intake.
3. Better long-term tolerability – compared to smegglutinin, it has milder gastrointestinal side effects and is suitable for long-term use.

 

2. Latest Clinical Research Data: The SURMOUNT Study Reveals the " Most Powerful Weight Loss Drug "

The SURMOUNT-1 study ( 2022 ) was a global phase III clinical trial in obese or overweight patients (without diabetes) that evaluated the effects of different doses of telpoide on weight management.

Research Design:

•       The trial included 2,539 patients with a BMI ≥27 (overweight) or BMI ≥30 (obese) and no history of diabetes.

•       Subjects were divided into four groups and received doses of telpolide of 2.5 mg , 5 mg , 10 mg and 15 mg , respectively, once a week for 72 weeks.

•       The primary evaluation indicators were the percentage of weight loss and long-term safety .

Study results (after 72 weeks):

dose	Average weight loss (%)	Proportion of participants who lost ≥20% of their body weight
5mg	15.0%	36%
10mg	19.5%	51%
15mg	22.5%	57%

      •    The average weight loss in the 15mg telpotassium group was 22.5% , making it the most effective weight loss drug currently approved by the FDA .

•       57% of the participants experienced a weight loss of more than 20% , compared to only 36% ( 16.9% ) of the participants in the same study with smegglutinin.

•       Even in the 5mg low-dose group, subjects still lost an average of 15% weight , which is higher than the effect of most traditional weight loss drugs.

📌 Conclusion: Compared with smegglutide, telpolide can bring more significant weight loss in the same time period, and at high doses, the weight loss exceeds 20% .

 

3. Why is telpolide more effective than smegglutide?

( 1 ) Dual activating mechanism: GLP-1 + GIP improve fat burning efficiency

•       Smegglutinin ( a GLP-1 monoagonal agonist) primarily acts on the brain to reduce appetite, but its direct effect on fat metabolism is limited.

•       Telpoeptide ( a GLP-1 + GIP dual agonist) additionally activates GIP receptors, improves insulin sensitivity, promotes lipolysis, and enables the body to utilize stored fat more effectively.

( 2 ) Better long-term tolerance

•       The SURMOUNT study showed that the incidence of gastrointestinal side effects (such as nausea and vomiting) of telpotetide was lower than that of smegglutide , allowing more patients to adhere to long-term medication.

( 3 ) Stronger ability to maintain weight in the long term

•       Studies have shown that patients who used telpolide for 72 weeks were able to maintain a lower body weight after discontinuing the drug, while smegglutide had a higher rebound rate after discontinuation .

 

4. Who is suitable for telpoeptide?

📌 Suitable for:

•       For people who want to lose a significant amount of weight (goal > 20% weight loss).

•       For users who are not satisfied with the effects of Smegglutide (weight loss less than 15% ).

•       People with insulin resistance or prediabetes need to improve their metabolic health.

•       People with sensitive gastrointestinal tracts who wish to use GLP-1 drugs long-term .

📌 Unsuitable for:

•       Patients with medullary thyroid carcinoma ( MTC ) or MEN 2 syndrome.

•       Pregnant or breastfeeding women.

•       Patients with severe gastrointestinal diseases (such as gastroparesis).

 

5. Conclusion: Why is telpoide the most powerful weight loss drug currently available?

1. Stronger weight loss effect than semaglutide – after 72 weeks, the average weight loss at the 15mg dose was 22.5% , significantly better than semaglutide ( 16.9% ).
2. The unique GLP-1 + GIP mechanism reduces appetite while promoting fat breakdown and improving insulin sensitivity.
3. Better long-term tolerability — fewer side effects than traditional GLP-1 agonists, making it suitable for long-term use.
4. Stronger weight maintenance ability – the risk of weight rebound after discontinuation of the drug is lower than that of semaglutide.

📌 In summary, telpolide is not only the most potent weight loss drug currently approved by the FDA , but it also demonstrates superior effects in improving metabolic health and long-term weight management.